COMBINATION OF NIRAPARIB AND ANLOTINIB IN PATIENTS WITH RECURRENT OR METASTATIC ENDOMETRIAL CANCER: AN OPEN-LABEL, SINGLE-ARM, TWO-STAGE, PHASE II STUDY

被引：0
作者：
Ren, Yulan [1 ,2 ]
Lu, Jing [2 ,3 ]
Tian, Wenjuan [1 ,2 ]
Li, Haiming [2 ,3 ]
Wang, Huaying [1 ,2 ]
机构：
[1] Fudan Univ, Dept Gynecol Oncol, Shanghai Canc Ctr, Shanghai, Peoples R China
[2] Fudan Univ, Dept Oncol, Shanghai Med Coll, Shanghai Canc Ctr, Shanghai, Peoples R China
[3] Fudan Univ, Dept Radiol, Shanghai Canc Ctr, Shanghai, Peoples R China
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2022年 / 32卷
关键词：
D O I：
10.1136/ijgc-2022-igcs.239
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP148/#437
引用
收藏
页码：A107 / A107
页数：1
相关论文
共 50 条
  • [31] An Open-Label, Single-Arm Phase Two Trial of Gefitinib in Patients With Advanced or Metastatic Castration-Resistant Prostate Cancer
    Pezaro, Carmel
    Rosenthal, Mark A.
    Gurney, Howard
    Davis, Ian D.
    Underhill, Craig
    Boyer, Michael J.
    Kotasek, Dusan
    Solomon, Benjamin
    Toner, Guy C.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2009, 32 (04): : 338 - 341
  • [32] Nintedanib for patients with lymphangioleiomyomatosis: a phase 2, open-label, single-arm study
    Harari, Sergio
    Elia, Davide
    Caminati, Antonella
    Geginat, Jens
    Luisi, Francesca
    Pelosi, Giuseppe
    Specchia, Claudia
    Torre, Olga
    Trevisan, Roberta
    Vasco, Chiara
    Zompatori, Maurizio
    Cassandro, Roberto
    LANCET RESPIRATORY MEDICINE, 2024, 12 (12) : 967 - 974
  • [33] A SINGLE-ARM, OPEN-LABEL, PHASE II STUDY EVALUATING THE EFFICACY AND SAFETY OF ABEMACICLIB IN PATIENTS WITH RECURRENT OLIGODENDROGLIOMA: TRIALS IN PROGRESS
    Bagley, Stephen
    Nasrallah, MacLean
    O'Rourke, Donald
    Hussain, Jasmin
    Maloney-Wilensky, Eileen
    Prior, Timothy
    Brem, Steven
    Desai, Arati
    NEURO-ONCOLOGY, 2019, 21 : 219 - 219
  • [34] Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II Study
    Mao, Lili
    Fang, Meiyu
    Chen, Yu
    Wei, Xiaoting
    Cao, Jun
    Lin, Jing
    Zhang, Peng
    Chen, Ling
    Cao, Xiao
    Chen, Yujun
    Guo, Jun
    Si, Lu
    CLINICAL CANCER RESEARCH, 2022, 28 (21) : 4642 - 4648
  • [35] Efficacy and safety of niraparib in combination with anlotinib based on CA 125 level in newly diagnosed ovarian cancer: An open-label, single arm, multicenter, prospective phase II trial
    Wu, Ming
    Li, Lei
    Chao, Xiaopei
    Chen, Xiaojing
    Ma, Shuiqing
    Tan, Xianjie
    Zhong, Sen
    Shang, Xiao
    GYNECOLOGIC ONCOLOGY, 2023, 176 : S175 - S175
  • [36] Toripalimab combined with bevacizumab and chemotherapy for refractory, recurrent or metastatic cervical cancer: preliminary results of a single-arm, open-label, phase II trial
    Peng, Peng
    Yao, Hairong
    Liu, Dantong
    He, Yonglan
    Liu, Shikai
    Xiang, Yang
    GYNECOLOGIC ONCOLOGY, 2023, 176 : S29 - S29
  • [37] A prospective single-center, single-arm, open-label, phase II study of sintilimab and anlotinib combined with chemotherapy in neoadjuvant treatment of resectable esophageal cancer
    Duan, Hongtao
    Wang, Zhaoyang
    Cao, Lili
    Zhu, Yifang
    Tong, Liping
    Yan, Xiaolong
    THORACIC CANCER, 2024, 15 (19) : 1471 - 1476
  • [38] An open-label, single-arm, multi-institutional phase II trial of avelumab for recurrent, metastatic nasopharyngeal carcinoma.
    Sacco, Assuntina Gesualda
    Messer, Karen
    Leidner, Rom S.
    Colevas, A. Dimitrios
    Nieva, Jorge J.
    Chau, Nicole Grace
    Nangia, Chaitali Singh
    Pinsky, Benjamin
    Gold, Kathryn A.
    Daniels, Gregory A.
    Cohen, Ezra E. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [39] Disitamab vedotin and zimberelimab combined with stereotactic body radiation therapy for the treatment of recurrent, metastatic cervical cancer: A single-arm, open-label, phase II study
    Xu, Q.
    ANNALS OF ONCOLOGY, 2024, 35 : S592 - S593
  • [40] Anlotinib plus sintilimab as first-line treatment for patients with advanced colorectal cancer (APICAL-CRC): An open-label, single-arm, phase II study
    Wang, Z.
    Qin, B.
    Ye, C.
    Wang, M.
    Yuan, L.
    Yao, H.
    Jiao, X.
    Liu, K.
    Sun, L.
    Dai, W.
    Ling, Y.
    Wu, Y.
    Chen, S.
    Zhang, Y.
    Shi, D.
    Duan, X.
    Zhong, X.
    He, X.
    Zhai, W.
    Zang, Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S1433 - S1433
12345